| Identification | Back Directory | [Name]
Periplocoside | [CAS]
13137-64-9 | [Synonyms]
Periplocin
Periplocoside
3β-[(4-O-β-D-Glucopyranosyl-3-O-methyl-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-5β,14β-card-20(22)-enolide
Card-20(22)-enolide, 3-[(2,6-dideoxy-4-O-β-D-glucopyranosyl-3-O-methyl-β-D-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-, (3β,5β)- | [Molecular Formula]
C36H56O13 | [MDL Number]
MFCD01745141 | [MOL File]
13137-64-9.mol | [Molecular Weight]
696.825 |
| Questions And Answer | Back Directory | [Preparation]
Method 1: A method for preparing Periplocoside, comprising the following steps:
1) Drying the roots or stems of *Salix viminalis* at a predetermined temperature, and pulverizing the dried roots or stems to obtain *Salix viminalis* root or stem powder;
2) Placing a predetermined weight of *Salix viminalis* root or stem powder into a container, and adding a predetermined amount of ethanol solution to the container and stirring to obtain an ethanol mixture of *Salix viminalis* root or stem powder;
3) After ultrasonic extraction of the ethanol mixture of *Salix viminalis* root or stem powder, cooling it to room temperature, filtering it, and concentrating the filtrates to dryness to obtain salicylic acid. Method 2: A method for preparing cypermethrin, comprising the following steps: 1) Extraction of Perilla frutescens root bark: Perilla frutescens root bark is extracted using 40%–80% ethanol or 40%–100% methanol (v/v) as the extraction solvent. After extraction, the solvent is evaporated, water is added, and the mixture is filtered or centrifuged to obtain a clear aqueous solution of Perilla frutescens root bark; 2) Macroporous resin adsorption separation: The aqueous solution of Perilla frutescens root bark is adsorbed onto a macroporous resin and eluted with a gradient of 10%–95% ethanol. Each eluted fraction is collected, concentrated, and subjected to thin-layer chromatography. Color is developed using a cardiac glycoside-specific colorimetric reagent. The fractions containing cardiac glycosides are collected and combined; 3) High-performance liquid chromatography (HPLC) preparation and separation: The cardiac glycoside fraction was prepared by HPLC using a reversed-phase column with a mobile phase of methanol:water at a volume ratio of 30-60:70-40 or acetonitrile:water at a volume ratio of 15-40:85-60. The elution curve was monitored at 217-220 nm using an ultraviolet detector to guide product collection. The collected solution was concentrated and dried to obtain Periplocoside. |
| Chemical Properties | Back Directory | [Melting point ]
205°C | [alpha ]
D20 +32° | [Boiling point ]
610.7°C (rough estimate) | [density ]
1.1241 (rough estimate) | [refractive index ]
1.7500 (estimate) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO : 250 mg/mL (358.77 mM; Need ultrasonic) | [form ]
powder | [pka]
12.89±0.70(Predicted) | [color ]
White | [Water Solubility ]
7.937g/L(cold water) | [InChIKey]
KWBPKUMWVXUSCA-WVOVULELNA-N | [SMILES]
O1CC(=CC1=O)[C@@H]2[C@@]3([C@@](C4C([C@@]5([C@@](C[C@H](CC5)O[C@@H]6OC([C@H](C(C6O)OC)O)CO[C@H]7C(O[C@@H](CC7O)O)C)(CC4)O)C)CC3)(CC2)O)C |
| Safety Data | Back Directory | [WGK Germany ]
WGK 3 | [Storage Class]
6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | [Hazard Classifications]
Acute Tox. 2 Inhalation
Acute Tox. 2 Oral
STOT RE 2 | [Toxicity]
LD in rabbits, rats (mg/kg): 10, 480 s.c. (MacKeith) |
| Hazard Information | Back Directory | [Chemical Properties]
Soluble in methanol and DMSO Derived from Periploca odorifera | [Uses]
Periplocin can be used to improve bone health to prevent, alleviate, or treat osteoporosis. | [in vivo]
Periplocin (5-20 mg/kg; intraperitoneal injection; daily; for 14 days; female SCID mice) treatment represses the growth of hepatocellular carcinoma (HCC) in xenograft tumor model in mice[2]. | Animal Model: | Female SCID mice (6-8 weeks old) injected with Huh-7 cells[2] | | Dosage: | 5 mg/kg, 20 mg/kg | | Administration: | Intraperitoneal injection; daily; for 14 days | | Result: | Repressed the growth of hepatocellular carcinoma (HCC) in xenograft tumor model in mice.
|
|
|
|